The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update.

Autor: Perrin RJ; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA., Franklin EE; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA., Bernhardt H; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA., Burns A; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA., Schwetye KE; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA., Cairns NJ; Living Systems Institute, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, UK., Baxter M; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA., Weiner MW; Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.; Department of Medicine, University of California San Francisco, San Francisco, California, USA.; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.; Department of Neurology, University of California San Francisco, San Francisco, California, USA., Morris JC; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.; Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov; Vol. 20 (11), pp. 7859-7870. Date of Electronic Publication: 2024 Oct 01.
DOI: 10.1002/alz.14253
Abstrakt: Introduction: Biomarkers for Alzheimer's disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD neuropathologies; for this, neuropathologic examinations and annotated tissue samples are essential.
Methods: We conducted clinicopathologic correlation for the first 100 Alzheimer's Disease Neuroimaging Initiative (ADNI) Neuropathology Core (NPC) cases.
Results: Clinical syndromes in this cohort showed 95% sensitivity and 79% specificity for predicting high/intermediate ADNC, a 21% false positive rate, and a ∼44% false negative rate. In addition, 60% with high/intermediate ADNC harbored additional potentially dementing co-pathologies.
Discussion: These results suggest that clinical presentation imperfectly predicts ADNC and that accurate prediction of high/intermediate ADNC does not exclude co-pathology that may modify presentation, biomarkers, and therapeutic responses. Therefore, new biomarkers are needed for non-AD neuropathologies. The ADNI NPC supports this mission with well-characterized tissue samples (available through ADNI and the National Institute on Aging) and "gold-standard" diagnostic information (soon to include digital histology).
Highlights: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Neuropathology Core (NPC) brain donation cohort now exceeds 200 cases. ADNI NPC data in National Alzheimer's Coordinating Center format are available through the Laboratory of Neuro Imaging. Digitized slide files from the ADNI NPC will be available in 2025. Requests for ADNI brain tissue samples can be submitted online for ADNI/National Institute on Aging evaluation. Clinical diagnoses of Alzheimer's disease (AD)/AD and related dementias (ADRD) do not always predict post mortem neuropathology. Neuropathology is essential for the development of novel AD/ADRD biomarkers.
(© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: